ASX-Dividend-Report-Banner

Complete Genomics' DNBSEQ-T20x2RS* Named "Next Generation Sequencing Solution of the Year" by 2023 BioTech Breakthrough Awards Program

November 09, 2023 01:00 AM AEDT | By Cision
 Complete Genomics' DNBSEQ-T20x2RS* Named
Image source: Kalkine Media

Third Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

SAN JOSE, Calif., Nov. 8, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced it is the recipient of the 2023 "Next Generation Sequencing Solution of the Year" award in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes life sciences and biotechnology companies, products and services around the globe.

Complete Genomics' unveiling of its DNBSEQ-T20x2RS* in 2023 marked the first time in the industry that a high throughput sequencer reduced the price of genome sequencing to less than $100, or less than $1 per gigabyte.

"Our DNBSEQ-T20x2RS* is driving the development and expansion of the global genomics industry as we accelerate our understanding of the human genome and its medical applications. When we increased accessibility to genetic information through lower DNA sequencing costs to researchers, we fundamentally reshaped the industry dynamics," said Dr. Radoje (Rade) Drmanac, Co-Founder and Chief Scientific Officer of Complete Genomics.

In addition to making sequencing more affordable, opening it up to new clinical applications, the DNBSEQ-T20x2RS* will also enable broader use of the technology on a larger number of samples, with deeper sequencing per sample which yields more informative results.

Complete Genomics is able to offer the DNBSEQ-T20x2x2RS* at a competitive price because it's powered by dip-immersion biochemistry, which significantly reduces sequencing reagent usage, resulting in comparative savings of more than 60%. Using two-color sequencing, DNBSEQ-T20x2RS* saves 50% of optical, computing, storage and broadband resources compared to four-color technology, which contributes to significant cost savings.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year's program attracted more than 1,350 nominations from over 12 different countries throughout the world.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput sequencing technology development since its inception in 2005. Our products have powered over 6,200 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

* Complete Genomics' DNBSEQ sequencing platforms are for research use only and not for use in diagnostic procedures.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.